How Artificial Intelligence accelerated the development of the Covid-19 vaccine 

28/04/2021
How AI accelerated

Summary

It was incredible! Within 41 days of identifying, isolating and fully sequencing the Covid-19 virus, pharmaceutical company Moderna had delivered a vaccine candidate. To top this, the company did all of this in January and February 2020 – a full month before lockdowns began in most parts of the world.

It was incredible! Within 41 days of identifying, isolating and fully sequencing the Covid-19 virus, pharmaceutical company Moderna had delivered a vaccine candidate. To top this, the company did all of this in January and February 2020 – a full month before lockdowns began in most parts of the world. 1

It was thanks to a mixture of Artificial Intelligence (AI) algorithms and advanced analytics that this feat was achieved. But why should it not surprise us?

How-AI-accelerated-EN-01

 

AI is making what is extraordinary, seem almost ordinary

AI is now being used widely in biotech. According to the Genetic Engineering & Biotechnology News, it is already being used for "drug target identification, drug screening, image screening and predictive modelling. It is also being used to comb through scientific literature and manage huge amounts of critical clinical trial data that is now produced".4

How-AI-accelerated-EN-02

How-AI-accelerated-EN-03

How-AI-accelerated-EN-04

How-AI-accelerated-EN-05

How-AI-accelerated-EN-06

Johnson & Johnson and Pfizer are already using IBM Watson to analyse patient data and recommend better treatment options.10

When it comes to oncology, IBM Watson is able to analyse the meaning and context of both structured and unstructured data in clinical notes and reports that might be important for selecting the right treatment. By combining data from a patient's file with clinical expertise, external research and data, the best treatment for the patient can be selected.11

IBM has also launched Medical Sieve, a cognitive medical assistant with analytical  reasoning capabilities and a range of clinical knowledge. It is being used in clinical decision-making in radiology and cardiology, and can analyse radiology images to spot and detect problems faster and more reliably.12

Personalised and precision medicine will need a myriad of disruptive technologies to work on a scale that is cost effective and practical. The boom in data in the information age, coupled with the advances being made in AI, could therefore be a real game changer. 

AI is making its presence felt in biotech, in ways that were unimaginable a decade ago. This is arguably just the beginning. The potential therefore should not be under-estimated.

 

Reference
1. Kelly, M. (2020, November 24). Lessons from Moderna: Leverage the Power of Artificial Intelligence. Stern Speakers. 
2. History of AI in medicine, Gastrointestinal Endoscopy Volume 92, No. 4 : 2020
3. Vella, H. (2019, January 2). The Institution of Engineering and Technology. Engineering and Technology. 
4. Shaffer, C. (2020, April 16). Artificial Intelligence Is Helping Biotech Get Real. GEN - Genetic Engineering and Biotechnology News. 
5. Terry, M. (2019, June 18). Sanofi and Google Partner on Digital Health and Real-World Evidence Analysis. BioSpace. 
6. CB Insights. (2020, June 26). Big Tech Is Coming For Pharma. CB Insights Research. 
7. Novartis.   
8. Hale, C. (2020, March 13). IBM Watson Health to tap EBSCO’s DynaMed libraries for a combined AI drug information suite. FierceBiotech. 
9. Payne, A. (2020, September 22). The role of AI in advancing personalized healthcare. TechRadar. 
10. Johnson & Johnson to IBM: ‘Watson, come here. I want you.’ (2014, October 11). Fortune.  
11. Motzer RJ, Barrios CH, Kim TM, et al. Piloting IBM Watson Oncology within Memorial Sloan Kettering’s regional network. J Clin Oncol [Internet]. 2014;32(25):2765–2772.
12. Syeda-Mahmood T, Walach E, Beymer D, et al. Medical sieve: a cognitive assistant for radiologists and cardiologists. Proc SPIE - Prog Biomed Opt Imaging [Internet]. 2016;9785.

 

> download

 

 

The Fantasy World of Intelligent Cities

28/06/2021

Summary

Cars speeding in the sky, people in whimsical fashion, metallic skyscrapers – these are futuristic imaginations of cityscape in movies and theatres. Living in a metropolis yourself, have you wondered how cities will look like in the future?

Allianz Global Investors

You are leaving this website and being re-directed to the below website outside Singapore. This does not imply any approval or endorsement of the information by Allianz Global Investors Singapore Limited contained in the redirected website nor does Allianz Global Investors Singapore Limited accept any responsibility or liability in connection with this hyperlink and the information contained herein. Please keep in mind that the redirected website may contains funds and strategies not authorized for offering to the public of Singapore. Besides, please also take note on the redirected website’s terms and conditions, privacy and security policies, or other legal information. By clicking “Continue”, you confirm you acknowledge the details mentioned above and would like to continue accessing the redirected website. Please click “Stay here” if you have any concerns.

Welcome to Allianz Global Investors

Select your role
  • Individual Investor
  • Intermediaries
  • Institutional Investor
  • It contains legal and regulatory notices relevant to the information contained on this website. By accessing this website, you agree to be bound by the following terms and conditions. Please discontinue your access to this website immediately if you do not accept any of these terms or conditions.


    Investments

    The content of this website is for informational purposes only and does not have any regard to the specific investment objectives, financial situation or particular needs of any particular person.

    Advice should be sought from a financial adviser regarding the suitability of any fund before purchasing units in the fund. In the event that you choose not to seek advice from a financial adviser, you should consider whether the fund is suitable for you. Prices of funds and income from them may fall or rise and cannot be guaranteed.

    Past performance of any fund or manager/ sub-manager of the fund are not necessarily indicative of future performance.

    Prospectuses for funds registered with the Monetary Authority of Singapore under the Authorised Scheme and Recognised Scheme are available, and may be obtained from Allianz Global Investors Singapore Limited or its appointed distributors. Investors should read the prospectuses before investing in such funds.


    No Reliance

    Although Allianz Global Investors Singapore Limited has taken all reasonable care that the information contained within the website is accurate at the time of publication, no representation or warranty (including liability towards third parties), expressed or implied, is made as to its accuracy, reliability or completeness by Allianz Global Investors Singapore Limited or its contractual partners.

    Opinions and any other contents on this website are provided by Allianz Global Investors Singapore Limited for personal use and informational purposes only and are subject to change without notice.

    Nothing contained in the website constitutes investment, legal, tax or other advice nor is to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision.


    No Warranty

    The information and opinions contained on the website are provided without any warranty of any kind, either expressed or implied, to the fullest extent pursuant to applicable law. Allianz Global Investors Singapore Limited further assumes no responsibility for, and makes no warranties that, functions contained on the website will be uninterrupted or error-free, that defects will be corrected, or that the website or the servers that make it available will be free of viruses or other harmful components.


    Liability Waiver

    Under no circumstances, including , but not limited to, negligence, shall Allianz Global Investors Singapore Limited be liable for any special or consequential damages that result from the access or use of, or the inability to access or use, the materials at the website.


    Linked Sites

    Allianz Global Investors Singapore Limited has not reviewed any websites which link to this website, and is not responsible for the contents of off-site pages linked to from this website or any other websites linked to this website. Following links to any off-site pages or other websites shall be entirely at your own risk.

    The only exception to the above is that Allianz Global Investors Singapore Limited will ensure that all our electronic prospectuses comply with the requirements for electronic prospectuses set out in the Guidelines on Offer of Securities made through the Internet issued by the Monetary Authority of Singapore.


    Copyright

    Copyright to this website is owned by Allianz Global Investors Singapore Limited. The copyrights of third parties are reserved. You may download or print a hard copy of individual pages and/or sections of the website, provided that you do not remove any copyright or other proprietary notices. Any downloading or other copying from the website will not transfer title of any software or material to you. You may not reproduce (in whole or part), transmit (by electronic means or otherwise), modify, hyperlink or use for any public or commercial purpose the website without the prior permission of Allianz Global Investors Singapore Limited.

    All trademarks, service marks and logos on this website are the property of Allianz Global Investors Singapore Limited and other third party proprietors where applicable. Nothing on this website shall be construed as granting any license or right to use any image, trademark, service mark or logo, and Allianz Global Investors Singapore Limited will enforce such rights to the full extent of applicable law.


    Money Laundering

    As a result of money laundering and other regulations, additional documentation for identification purposes may be required when you make your investment.


    Governing Law and Jurisdiction

    These Terms and Conditions governing Allianz Global Investors Singapore Limited's website shall be governed by and construed in accordance with the laws of the Republic of Singapore. By accessing this website's online services, you agree that in relation to any legal action or proceedings arising out of or in connection with these said terms and conditions, you hereby irrevocably submit to the jurisdiction of the courts of the Republic of Singapore.

    Approved for issue by Allianz Global Investors Singapore Limited, 79 Robinson Road, #09-03, Singapore 068897. Company Regn. No. 199907169Z.

    You may face minimal or no returns or suffer total loss of their investments if both the guarantor and the note issuer default.

     

Please indicate you have read and understood the Important Notice.